The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

Antengene’s Xpovio NDA has gained approval from the Indonesia National Agency of Drug and Food Control for three indications.

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

Following a year of significant progress and execution across our pipeline, we remain well positioned to deliver on our mission to bring ...

Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with ...